STAT Inhibitors: 2018 Pipeline Insights - Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type - ResearchAndMarkets.com

July 30, 2018

DUBLIN--(BUSINESS WIRE)--Jul 30, 2018--The “STAT Inhibitors- Pipeline Insights, 2018” report has been added to ResearchAndMarkets.com’s offering.

This report outlays comprehensive insights of present scenario and growth prospects across STAT Inhibitors.

A detailed picture of the pipeline landscape is provided with summation of data from multiple sources with complete analysis by development stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 15+ active products with more than 8 companies involved. Two of the key players include Napabucasin of Boston Biomedical and Bardoxolone methyl of Reata Pharmaceuticals.

Products covered by Phase

Phase III, Phase II, Phase I IND Pre-clinical & Discovery Inactive (Dormant and Discontinued)

Overview of pipeline development activities for STAT Inhibitors

Pipeline analysis of therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and pre-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Therapeutic segmentation of products for STAT Inhibitors. The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this mechanism.


Provides an overview of therapeutic pipeline activity for STAT Inhibitors across the complete product development cycle including all clinical and non-clinical stages It comprises of detailed profiles of STAT Inhibitors therapeutic products with key coverage of developmental activities including licensing & collaboration deals, patents issued, designations, technologies and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across STAT Inhibitors

Key Topics Covered

Executive Summary Overview Introduction Structure of STAT Protein Mechanism of Action STAT Inhibitor Mechanism Functions of STAT Proteins Diseases Pipeline Therapeutics Competitive Landscape Comparative Analysis Late Stage Products (Phase III) Comparative Analysis Napabucasin: Boston Biomedical Product Description Research and Development Product Development Activities The list continues.. Mid Stage Products (Phase II) Comparative Analysis OPB-111077: Otsuka Product Description Research and Development The list continues.. Early Stage Products (Phase I & IND) Comparative Analysis Pre-clinical and Discovery Products Comparative Analysis Therapeutic Assessment Assessment by Product Type Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type Dormant and Discontinued Products Comparative Analysis Appendix

Companies Featured

Boston Biomedical Reata Pharmaceuticals Otsuka GLG Pharma Ionis Pharmaceuticals StemMed Moleculin Biotech Glactone Pharma Singh Biotechnology Janpix Bio

For more information about this report visit https://www.researchandmarkets.com/research/kx4qsz/stat_inhibitors?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180730005611/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/30/2018 12:48 PM/DISC: 07/30/2018 12:48 PM


Update hourly